Graham Juan's Form 4/A amendment
AmendedKyntra Bio, Inc.KYNB · filed Dec 15, 2022
- Accession no.
- 0001209191-22-061485
- Filed
- Dec 15, 2022
- Trade date
- Dec 9-12, 2022
- Filing delay
- 6 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
- Original filed
- Dec 14, 2022
This filing lists 2 non-derivative transactions. Open-market sales total $32.0K. It was filed 6 days after the trade.
This amendment replaces 0001209191-22-061328 (filed Dec 14, 2022).
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Graham JuanCIK 0001879223 | Officer (Chief Financial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 9, 2022 | Common Stock | SSaleDisposed | −781 | $14.89F2 | −$11,629.09 | 49,369 | Direct | |
| Dec 12, 2022 | Common Stock | SSaleDisposed | −1,407 | $14.50 | −$20,401.5 | 47,962 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I.
- F2
These shares were sold in multiple transactions on the reported date with prices ranging from $14.667 to $14.8936 resulting in a weighted average price of $14.89. Upon request, the reporting person will provide to the Commission staff or a security holder of the Issuer the number of shares sold and the sale price for each separate transaction.
Referenced by the price of 1 transaction in Table I.
- F3
Shares sold pursuant to a 10b5-1 plan.
Remarks
This amendment is being file to include the sales price range and to update Column 5 for number of beneficially held shares.